乌鸦传媒

<乌鸦传媒 class='mpt-top_cat_title'>Pulmonology >

Lung Cancer

News, opinions and meeting coverage in pulmonology.

FDA APPROVED osimertinib (Tagrisso) over a computer rendering of lung cancer.

<乌鸦传媒>FDA Expands Approval of Osimertinib in Lung Cancer

EGFR inhibitor now indicated for unresectable stage III disease following chemoradiotherapy

A photo of test tubes of blood lying on a test form with CANCER stamped in red at the bottom.

<乌鸦传媒>Cancer Diagnoses Slow to Recover From Effects of COVID Pandemic

Actual rates for 2021 lagged behind projections

WCLC over a photo of San Diego Conference Center in San Diego, CA.

<乌鸦传媒>Antibody Drug-Conjugate Shows Promising Activity in Extensive-Stage SCLC

Objective response rate was 55% with 12-mg/kg ifinatamab deruxtecan

WCLC over a photo of San Diego Conference Center in San Diego, CA.

<乌鸦传媒>Added Plinabulin Boosts OS as Later-Line Treatment for EGFR Wild-Type NSCLC

However, plinabulin plus docetaxel still "not ready for prime time," expert says

WCLC over a photo of San Diego Conference Center in San Diego, CA.

<乌鸦传媒>MET Inhibitor Increases Osimertinib Activity in EGFR+ Advanced NSCLC

Absolute improvement of almost 30%, doubling of duration of response with savolitinib

WCLC over a photo of San Diego Conference Center in San Diego, CA.

<乌鸦传媒>Perioperative Nivolumab Boosts EFS Versus Neoadjuvant-Only Nivolumab in NSCLC

Two-trial analysis shows about a 40% decreased risk of disease recurrence or death

WCLC over a photo of San Diego Conference Center in San Diego, CA.

<乌鸦传媒>Ivonescimab Tops Pembrolizumab in PD-L1-Positive, Advanced NSCLC

Novel agent nearly halved risk of progression as first-line therapy in phase III trial

WCLC over a photo of San Diego Conference Center in San Diego, CA.

<乌鸦传媒>Novel Drugs Boost Immunotherapy Activity in Resectable Lung Cancer

Add-on ADC, monoclonal antibody consistently increase pCR versus PD-1 inhibitor plus chemotherapy

A photo composite of vials of Opdivo and Yervoy over a computer rendering of lung cancer.

<乌鸦传媒>Trial Questions Role of Dual Immunotherapy in First-Line NSCLC

In Japanese trial, nivolumab-ipilimumab didn't improve OS versus pembrolizumab, had more toxicity

A CT scan of healthy lungs.

<乌鸦传媒>Researchers Challenge USPSTF's Lung Cancer Screening Criteria

Alternate criteria based on years of smoking has higher sensitivity and specificity, study says

FDA APPROVED lazertinib (Lazcluze) over a computer rendering of lung cancer.

<乌鸦传媒>Targeted First-Line Combo Approved for EGFR-Mutated Lung Cancer

Lazertinib plus amivantamab improved PFS by about 7 months versus single-agent osimertinib

A photo of a box of prednisolone tablets.

<乌鸦传媒>Higher Steroid Dose for ICI Toxicity Harms Cancer Survival, Analysis Suggests

More data for discussion of controversial association between steroids, immunotherapy

FDA APPROVED durvalumab (Imfinzi) over a computer rendering of a transparent body with lung cancer highlighted.

<乌鸦传媒>FDA Expands Durvalumab Label to Operable Lung Cancer

PD-L1 checkpoint inhibitor approved for use in NSCLC before and after surgery

A computer rendered cutaway of a colonoscopy.

<乌鸦传媒>Cancer Screening Costs Over $43 Billion a Year in the U.S., Study Estimates

Colorectal cancer screening accounted for 64% of the total amount

FDA ODAC durvalumab (Imfinzi) over a computer rendering of an antibody attacking lung cancer cells.

<乌鸦传媒>FDA Panel Supports More Clarity in NSCLC Perioperative Immunotherapy Trials

Committee unanimously backs mandating trial design to distinguish effects of therapy phases

A close up photo of a man smoking an ecigarette.

<乌鸦传媒>Vapers May Be Less Likely to Undergo Lung Cancer Screening

"Former smokers who use e-cigarettes remain at increased risk of lung cancer," researchers say

A computer rendering of a liver under a red umbrella.

<乌鸦传媒>Real-World Analysis Identifies Meds Tied to Higher Risk of Liver Injury

Case reports may not be as reliable, researchers say

A photo of the HealthCare.gov website.

<乌鸦传媒>Court: Some Employers Can Exclude PrEP, Cancer Screenings From Insurance Coverage

Not all preventive care recommended by the USPSTF is threatened by the narrow ruling, however

A computer rendering of a transparent body with a tumor in the lungs highlighted.

<乌鸦传媒>Anti-PD-L1 Plus Targeted Agent No Better Than Chemo for Resistant NSCLC

No significant difference between atezolizumab-cabozantinib, docetaxel for OS, PFS, response

A close up photo of a woman smoking a cigarette.

<乌鸦传媒>Early Menopause Tied to Higher Risk of Respiratory Mortality

Greatest risk observed for women with bilateral oophorectomy

A computer rendering of a lung tumor.

<乌鸦传媒>Another KRAS Inhibitor Scores an Early Win in Advanced Non-Small Cell Lung Cancer

Half of patients responded, but editorialists call for new directions in therapy development

A scanning electron microscope image of a dendritic cell

<乌鸦传媒>Dendritic Cell Therapy Offers No Survival Advantage in Pleural Mesothelioma

Immunotherapy may have been given too late, researchers suggested

An advertisement for lung cancer screening on the back of a kiosk in New York City.

<乌鸦传媒>Lung Cancer Screening Rates Remain Low in the U.S., Especially in the South

But one study showed that patient navigation added to usual care may increase uptake

<乌鸦传媒>Artery Inflammation and CV Events; Stepped Palliative Care for Lung Cancer Patients

Also in TTHealthWatch: diets and medicine in IBS and active surveillance in prostate cancer

ASCO over a photo of McCormick Place in Chicago, IL

<乌鸦传媒>Limited-Stage SCLC Gets a New Standard of Care With Consolidation Durvalumab

Median OS was 55.9 months in the durvalumab group compared with 33.4 months in the placebo group

ASCO over a photo of McCormick Place in Chicago, IL

<乌鸦传媒>'Practice Changing' Trial for Inoperable Locally Advanced NSCLC

EGFR testing now needed for all patients with stage III disease, experts say

ASCO over a photo of McCormick Place in Chicago, IL

<乌鸦传媒>Virtual and In-Person Palliative Care Equally Beneficial in Advanced Lung Cancer

No differences observed in quality of life metric, patient and caregiver satisfaction

ASCO over a photo of McCormick Place in Chicago, IL

<乌鸦传媒>Subcutaneous Amivantamab Plus Lazertinib Non-Inferior to IV Dosing in NSCLC

Unexpectedly offers a possible overall survival benefit, researchers say

ASCO over a photo of McCormick Place in Chicago, IL

<乌鸦传媒>Novel Bispecific in EGFR-Mutant Lung Cancer Boosts PFS After Targeted Agents

China-based trial may present a hurdle to FDA approval, however

ASCO over a photo of McCormick Place, in Chicago, IL

<乌鸦传媒>Unprecedented PFS Results in ALK-Positive Lung Cancer Trial

"We have not seen anything close to this," says expert

A close up photo of a man vaping.

<乌鸦传媒>Smoking Isn't the Only Source of Nicotine Addiction in Town

Emerging data suggest pharmacological interventions may help patients quit vaping

A close up photo of methylphenidate tablets.

<乌鸦传媒>Psychostimulant No Help in Relieving Cancer-Related Fatigue

No significant differences in outcomes between methylphenidate, placebo

FDA APPROVED tarlatamab (Imdelltra) over a computer rendering of small cell lung cancer

<乌鸦传媒>FDA OKs Novel BiTE Agent for Small Cell Lung Cancer

First-in-class tarlatamab achieved a 40% ORR in previously treated extensive-stage SCLC

A photo of the vial and packaging of nivolumab (Opdivo) over a computer rendering of lung cancer.

<乌鸦传媒>Perioperative Nivolumab Boosts EFS in Resectable Lung Cancer

CheckMate 77T trial shows 42% reduction in risk of tumor recurrence, progression, or death

A photo of Dr. Laurie Margolies demonstrating the Koios DS Smart Ultrasound software

<乌鸦传媒>Will AI Replace Radiologists, or Just Make Them Better Than Ever?

Opinions differ on how much physicians should be embracing the technology

A computer rendering of KRAS G12C mutation in non-small cell lung cancer

<乌鸦传媒>Glecirasib Shows Promising Efficacy in KRAS-Mutated NSCLC

Trend towards better response rate, PFS compared with approved KRAS inhibitors

A photo of Environmental Protection Agency Administrator Michael Regan speaking at event at Howard University, in Washington.

<乌鸦传媒>EPA Bans Consumer Use of Toxic Chemical Known to Cause Liver, Lung Cancers

Methylene chloride has killed at least 88 workers since 1980

A menthol cigarette in an ashtray.

<乌鸦传媒>White House Indefinitely Delays Plan to Ban Menthol Cigarettes

Biden administration has delayed the final rule several times recently

FDA APPROVED alectinib (Alecensa) over a computer rendering of lung cancer.

<乌鸦传媒>Alectinib Lands FDA Approval for Adjuvant Therapy in NSCLC

The ALK inhibitor reduced the risk of recurrence or death by 76% versus chemotherapy

AACR over a photo of San Diego Convention Center in San Diego, CA

<乌鸦传媒>Accelerated Aging Linked to Recent Increase in Early-Onset Solid Tumors

Strength of association increased in more recent birth cohorts

1

鈥�